title: Statin myopathy: a common dilemma not reflected in clinical trials.
abstract: Although statins are remarkably effective, they are still underprescribed because of concerns about muscle toxicity. We review the aspects of statin myopathy that are important to the primary care physician and provide a guide for evaluating patients on statins who present with muscle complaints. We outline the differential diagnosis, the risks and benefits of statin therapy in patients with possible toxicity, and the subsequent treatment options.
authors.affiliation: Internal Medicine Residency Program,The University of Utah, Salt Lake City, Utah, USA.
authors.forename: Genaro
authors.initials: G
authors.lastname: Fernandez
authors.forename: Erica S
authors.initials: ES
authors.lastname: Spatz
authors.forename: Charles
authors.initials: C
authors.lastname: Jablecki
authors.forename: Paul S
authors.initials: PS
authors.lastname: Phillips
mesh_terms: D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D018908:Muscle Weakness / Q000139:chemically induced / Q000628:therapy; D009135:Muscular Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D009220:Myositis / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D012206:Rhabdomyolysis / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors